Bristol-Myers Squibb 1Q

1Q Revenues: $4.8 billion (+11%)

1Q Earnings: $743 million (+16%)

Comments: U.S. and International sales increased 11% to $3.1 billion and $1.7 billion, respectively. Growth in the quarter was led by an increase in Plavix sales, up 16% to $1.7 billion, as well as the virology franchise. Baraclude sales were up 42% to $216 million, Reyataz sales were up 16% to $373 million, and Sustiva sales were $335 million (+15%). R&D expenses were flat at $910 million.